Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration

類似資料

• Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
  著者:: Hilal, Talal, 等
  出版事項: (2020)
• Potential Cost Implications for All US Food and Drug Administration Oncology Drug Approvals in 2018
  著者:: DeMartino, Patrick C., 等
  出版事項: (2020)
• An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate
  著者:: Chen, Emerson Y., 等
  出版事項: (2019)
• Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration’s Approval of Oncology Drugs
  著者:: Kim, Chul, 等
  出版事項: (2016)
• Oncology Drug Development and Approval of Systemic Anticancer Therapy by the U.S. Food and Drug Administration
  著者:: Martell, Robert E., 等
  出版事項: (2013)